MiNK Therapeutics, Inc.
INKT · XNASCIK 1840229fmd_1VT2THAT8KK19DAXKWVX3X928BManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Net interest income | – | (2) | 0 | 0 | 0 | 0 |
| Research and development | 10 | 14 | 23 | 15 | 6 | 6 |
| Compensation and benefits | – | – | – | (8) | (5) | (4) |
| Operating income | (15) | (28) | (31) | (23) | (11) | (13) |
| Interest expense | 2 | 2 | – | (0) | (0) | (0) |
| Other non-operating income (expense) | 1 | 0 | 3 | (0) | 0 | (0) |
| Net income | (16) | (30) | (28) | (22) | (11) | (12) |